91 related articles for article (PubMed ID: 23820828)
21. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
22. Exposure therapy, D-cycloserine, and functional magnetic resonance imaging in patients with snake phobia: a randomized pilot study.
Nave AM; Tolin DF; Stevens MC
J Clin Psychiatry; 2012 Sep; 73(9):1179-86. PubMed ID: 23059145
[TBL] [Abstract][Full Text] [Related]
23. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.
Kushner MG; Kim SW; Donahue C; Thuras P; Adson D; Kotlyar M; McCabe J; Peterson J; Foa EB
Biol Psychiatry; 2007 Oct; 62(8):835-8. PubMed ID: 17588545
[TBL] [Abstract][Full Text] [Related]
24. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder.
de Kleine RA; Hendriks GJ; Kusters WJ; Broekman TG; van Minnen A
Biol Psychiatry; 2012 Jun; 71(11):962-8. PubMed ID: 22480663
[TBL] [Abstract][Full Text] [Related]
25. Selective increase in the extracellular D-serine contents by D-cycloserine in the rat medial frontal cortex.
Fujihira T; Kanematsu S; Umino A; Yamamoto N; Nishikawa T
Neurochem Int; 2007; 51(2-4):233-6. PubMed ID: 17662507
[TBL] [Abstract][Full Text] [Related]
26. Enhancing exposure-based therapy from a translational research perspective.
Hofmann SG
Behav Res Ther; 2007 Sep; 45(9):1987-2001. PubMed ID: 17659253
[TBL] [Abstract][Full Text] [Related]
27. [Interaction of N-methyl-D-aspartate and Dopamine D1 receptors in modulation of passive avoidance extinction at mice with depressive-like state].
Dubrovina NI; Zinov'eva DV
Ross Fiziol Zh Im I M Sechenova; 2011 Jul; 97(7):700-7. PubMed ID: 21961294
[TBL] [Abstract][Full Text] [Related]
28. Delay aversion: effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and D-cycloserine.
van den Bergh FS; Bloemarts E; Groenink L; Olivier B; Oosting RS
Pharmacol Biochem Behav; 2006 Dec; 85(4):736-43. PubMed ID: 17208285
[TBL] [Abstract][Full Text] [Related]
29. Neuroinflammation-Induced Memory Deficits Are Amenable to Treatment with D-Cycloserine.
Liraz-Zaltsman S; Yaka R; Shabashov D; Shohami E; Biegon A
J Mol Neurosci; 2016 Sep; 60(1):46-62. PubMed ID: 27421842
[TBL] [Abstract][Full Text] [Related]
30. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
31. D-cycloserine enhances generalization of fear extinction in children.
Byrne SP; Rapee RM; Richardson R; Malhi GS; Jones M; Hudson JL
Depress Anxiety; 2015 Jun; 32(6):408-14. PubMed ID: 25775435
[TBL] [Abstract][Full Text] [Related]
32. Treatment of pediatric anxiety disorders.
Rapp A; Dodds A; Walkup JT; Rynn M
Ann N Y Acad Sci; 2013 Nov; 1304():52-61. PubMed ID: 24279893
[TBL] [Abstract][Full Text] [Related]
33. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans.
Onur OA; Schlaepfer TE; Kukolja J; Bauer A; Jeung H; Patin A; Otte DM; Shah NJ; Maier W; Kendrick KM; Fink GR; Hurlemann R
Biol Psychiatry; 2010 Jun; 67(12):1205-11. PubMed ID: 20303474
[TBL] [Abstract][Full Text] [Related]
34. Maintaining clinical relevance: considerations for the future of research into D-cycloserine and cue exposure therapy for addiction.
Das RK; Kamboj SK
Biol Psychiatry; 2012 Dec; 72(11):e29-30; author reply e31-2. PubMed ID: 22748617
[No Abstract] [Full Text] [Related]
35. D-cycloserine augmentation for behavioral therapy.
Shim SS; Hammonds MD; Vrabel MM
Am J Psychiatry; 2008 Aug; 165(8):1050. PubMed ID: 18676606
[No Abstract] [Full Text] [Related]
36. Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials.
Pawlak CR; Chen FS; Wu FY; Ho YJ
Kaohsiung J Med Sci; 2012 Aug; 28(8):407-17. PubMed ID: 22892161
[TBL] [Abstract][Full Text] [Related]
37. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
Tsai GE; Falk WE; Gunther J; Coyle JT
Am J Psychiatry; 1999 Mar; 156(3):467-9. PubMed ID: 10080566
[TBL] [Abstract][Full Text] [Related]
38. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury.
Yaka R; Biegon A; Grigoriadis N; Simeonidou C; Grigoriadis S; Alexandrovich AG; Matzner H; Schumann J; Trembovler V; Tsenter J; Shohami E
FASEB J; 2007 Jul; 21(9):2033-41. PubMed ID: 17351125
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.
Otto MW; Tolin DF; Simon NM; Pearlson GD; Basden S; Meunier SA; Hofmann SG; Eisenmenger K; Krystal JH; Pollack MH
Biol Psychiatry; 2010 Feb; 67(4):365-70. PubMed ID: 19811776
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
